The Role of Gadolinium in Triggering Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy

From: Archives of Pathology & Laboratory Medicine | Date: October 1, 2007| Author: Rosen, Paul Peter; Wu, Elizabeth; Solomon, Garron Joseph | Copyright information

To the Editor.-We recently published a case report entitled ''Nephrogenic Systemic Fibrosis Mimicking Inflammatory Breast Carcinoma'' in the January 2007 edition of the ARCHIVES.1 This scleromyxedema-like systemic fibrosing disorder, the cutaneous manifestations of which led to the former appellation nephrogenic fibrosing dermopathy, was first recognized in 1997. As we stated in our article, Cowper and colleagues had suspected deposition of a recently introduced material, such as a contrast a...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

The Role of Gadolinium in Triggering Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy
Archives of Pathology & Laboratory Medicine ; To the Editor.-We recently published a case report entitled ''Nephrogenic Systemic Fibrosis Mimicking Inflammatory Breast Carcinoma'' in the January 2007 edition of the ARCHIVES.1 This scleromyxedema-like systemic fibrosing disorder, the cutaneous manifestations of which led to the former
MR contrast tied to skin syndrome.(News)(magnetic resonance)
Internal Medicine News ; Gadolinium-based contrast agents, when given to patients with renal disease, have been associated with a rare, potentially fatal, sclerodermalike skin disease called nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy. On Dec. 22, the Food and Drug Administration issued a public
Researchers suggest NSF, transglutaminase expression link.(News)
Skin & Allergy News ; Increased expression of transglutaminase in patients with nephrogenic systemic fibrosis may offer new insight into the pathogenesis, treatment, and possibly prevention of the syndrome, according to the authors of a new study, Transglutaminases: The Missing Link in Nephrogenic Systemic Fibrosis. If
Chronic kidney disease: CT or MRI?
Applied Radiology ; Patients with reduced renal function are at risk of developing contrastinduced nephrotoxicity (CIN) following a contrast-enhanced computed tomography (CT) examination with an iodinated contrast agent1 and at risk of developing nephrogenic systemic fibrosis (NSF) after a contrast-enhanced magnetic
NSF-gadolinium cases centralized.(Policy & Practice)(nephrogenic systemic fibrosis )(Brief article)
Skin & Allergy News ; Discovery for 66 suits alleging that gadolinium-based contrast led to nephrogenic systemic fibrosis (NSF) has been consolidated in a federal court in Ohio. The plaintiffs allege that the gadolinium-based contrast agent used during magnetic resonance imaging led to NSE NSF has occurred only in
Gadolinium and kidney disease: are your patients at risk?(Clinical Consult)(Clinical report)
Nephrology Nursing Journal ; Q: Can the use of contrast materials for radiographic studies be harmful to patients with chronic kidney disease (CKD)? A: In the past few years there has been considerable concern in the nephrology community about the use of gadolinium-based contrast agents that are used as a contrast agent in
Nephrogenic Systemic Fibrosis Mimicking Inflammatory Breast Carcinoma
Archives of Pathology & Laboratory Medicine ; * Nephrogenic systemic fibrosis, previously known as nephrogenic fibrosing dermopathy, is a newly recognized systemic fibrosing disorder primarily affecting patients with chronic renal failure. Patients with skin involvement often develop papules and plaques with peau d'orange surface changes. The
Gadolinium Linked to Nephrogenic Systemic Fibrosis
The Journal of Nuclear Medicine ; In 2 articles appearing on November 8 online ahead of print in the Journal of the American Academy of Dermatology, researchers provided evidence suggesting a link between exposure to gadolinium-containing contrast agents and nephrogenic fibrosing dermopathy (NFD)/nephrogenic systemic fibrosis (NSF)
Contrast agents may pose danger in renal disease.(Clinical Rounds)(Disease/Disorder overview)
Family Practice News ; Gadolinium-based contrast agents, when given to patients with renal disease, have been associated with a rare, potentially fatal, sclerodermalike skin disease called nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy. The Food and Drug Administration issued a public health advisory
MR contrast agent poses danger in renal disease.(Clinical Rounds)
Pediatric News ; Gadolinium-based contrast agents, when given to patients with renal disease, have been associated with a rare, potentially fatal, scleroderma-like skin disease called nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy. On Dec. 22, the Food and Drug Administration issued a public